Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.67, $0.41 better than the analyst estimate of $4.26. Revenue for the quarter came in at $6.71 billion versus the consensus estimate of $6.69 billion.

GUIDANCE:

Amgen sees FY2021 EPS of $16.50-$17.10, versus the consensus of $16.43. Amgen sees FY2021 revenue of $25.8-26.2 billion, versus the consensus of $26 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)